Retatrutide vs Tirzepatide: Triple Agonist vs Dual Agonist Weight Loss
A detailed comparison of retatrutide (Eli Lilly LY3437943) and tirzepatide (Mounjaro, Zepbound). Retatrutide is an investigational GLP-1/GIP/glucagon triple receptor agonist; tirzepatide is the FDA-approved GLP-1/GIP dual agonist. Updated May 2026 with TRIUMPH-1 Phase 3 primary endpoint topline (28.3% at 12 mg / 80 wk, 30.3% at 104 wk in BMI ≥35, 19% at 4 mg).
Last updated: 2026-05-22
| Property | Retatrutide | Tirzepatide |
|---|---|---|
| Evidence Level | Level B | Level A |
| Regulatory Status | Investigational | FDA ApprovedFDA-approved May 2022 (Mounjaro) for type 2 diabetes; FDA-approved November 2023 (Zepbound) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity. |
| Category | Weight Management | Weight Management |
| Administration | Injectable | Injectable |
| Onset Time | Weeks (appetite suppression onset); peak weight loss at 48+ weeks | Appetite suppression onset within days to weeks; peak weight loss at 36–72 weeks |
| Half-Life | Approximately 7 days (once-weekly dosing design) | Approximately 5 days (once-weekly dosing) |
| Key Mechanism | Retatrutide's effects arise from simultaneous activation of three incretin and metabolic hormone receptor pathways: ... | Tirzepatide's metabolic effects arise from simultaneous activation of two distinct incretin hormone receptors: GLP... |
Retatrutide
- Evidence Level
- Level B
- Regulatory Status
- Investigational
- Category
- Weight Management
- Administration
- Injectable
- Onset Time
- Weeks (appetite suppression onset); peak weight loss at 48+ weeks
- Half-Life
- Approximately 7 days (once-weekly dosing design)
- Key Mechanism
- Retatrutide's effects arise from simultaneous activation of three incretin and metabolic hormone receptor pathways: ...
Tirzepatide
- Evidence Level
- Level A
- Regulatory Status
- FDA ApprovedFDA-approved May 2022 (Mounjaro) for type 2 diabetes; FDA-approved November 2023 (Zepbound) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity.
- Category
- Weight Management
- Administration
- Injectable
- Onset Time
- Appetite suppression onset within days to weeks; peak weight loss at 36–72 weeks
- Half-Life
- Approximately 5 days (once-weekly dosing)
- Key Mechanism
- Tirzepatide's metabolic effects arise from simultaneous activation of two distinct incretin hormone receptors: GLP...
Key Differences
Retatrutide and tirzepatide are both Eli Lilly incretin-based obesity therapeutics, but they differ at the receptor pharmacology level — and that difference appears to translate into the largest mean weight-loss magnitudes published for any pharmacotherapy class to date. Tirzepatide is the current FDA-approved standard of care for chronic weight management; retatrutide remains investigational as of May 2026, though the pivotal Phase 3 TRIUMPH-1 obesity trial met its primary endpoint on May 21 2026.
Receptor Pharmacology
Tirzepatide is a dual GLP-1/GIP receptor agonist. It activates both the glucagon-like peptide-1 (GLP-1) receptor — the same target as semaglutide — and the glucose-dependent insulinotropic polypeptide (GIP) receptor. The combination of incretin signaling produces greater appetite suppression and metabolic benefit than GLP-1 monotherapy.
Retatrutide is a triple agonist of GLP-1, GIP, and the glucagon receptor. The addition of glucagon receptor agonism is the structural innovation. While glucagon's classical role is to raise blood glucose, controlled glucagon receptor activation also increases energy expenditure (via thermogenesis and increased basal metabolic rate) and shifts hepatic substrate utilization. The triple-agonist hypothesis is that GLP-1/GIP-mediated appetite suppression combined with glucagon-mediated energy expenditure produces additive weight loss beyond what dual agonists achieve.
Weight Loss Magnitude (TRIUMPH-1 vs SURMOUNT-1)
The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) reported mean weight loss of approximately 24.2% at 48 weeks on the 12 mg dose. The pivotal Phase 3 TRIUMPH-1 obesity trial, reported by Lilly on May 21 2026, met its primary endpoint with the following topline numbers:
- 28.3% mean weight loss at 12 mg over 80 weeks (≈70.3 lbs)
- 30.3% at 104 weeks in the BMI ≥35 subgroup
- ≈19% mean weight loss at the previously untested 4 mg dose (≈47.2 lbs)
Tirzepatide produced a mean 22.5% body weight reduction at 72 weeks on the 15 mg dose in SURMOUNT-1 (Jastreboff et al., NEJM 2022).
The two drugs have not been compared head-to-head in a published RCT. The available data support a meaningfully greater mean weight-loss magnitude with retatrutide, but indirect cross-trial comparison must be interpreted with caution given different populations, trial durations, and analytic methods. Notably, the TRIUMPH-1 4 mg arm produced weight loss approaching the magnitude of tirzepatide's 15 mg arm — which, if borne out in the full data, would suggest a usable lower-dose tier with a potentially more favorable gastrointestinal tolerability profile.
Regulatory Status
Tirzepatide is FDA-approved: Mounjaro (May 2022) for type 2 diabetes; Zepbound (November 2023) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity. Retatrutide is investigational as of May 2026 — TRIUMPH-1 hit its primary endpoint on May 21 2026 and full results are expected at the ADA 2026 Scientific Sessions in June. FDA submission is anticipated following the complete Phase 3 readout, with potential approval in 2027 at the earliest.
Side Effect Profile
Both drugs share the GLP-1 class side-effect profile, dominated by gastrointestinal events (nausea, vomiting, diarrhea, constipation) most pronounced during dose escalation. Retatrutide's glucagon agonism introduces additional considerations: theoretical risk of glucose elevation (although in trials glycemic control improved overall, likely because GLP-1/GIP-mediated insulin and appetite effects dominate), and a higher reported incidence of certain dose-limiting adverse events compared with dual agonists. The FDA boxed warning for thyroid C-cell tumors applies to the GLP-1 class and is anticipated to apply to retatrutide based on class labeling precedent.
Cost and Access
Tirzepatide list price is approximately $1,000–$1,350 per month in the U.S., with insurance coverage growing but still variable for the obesity indication. Retatrutide pricing is not yet established because the drug is not commercially available; if approved, it would likely launch in a similar premium tier to tirzepatide. Both remain inaccessible to the global majority of people who could clinically benefit, an access issue that is part of the broader policy debate around incretin-class drugs.
Which Is Better For...?
Available now — tirzepatide is FDA-approved and commercially available with established prescribing infrastructure, insurance coverage pathways, patient savings programs, and a several-year post-approval safety record. Retatrutide remains investigational and is not legally available outside of clinical trials.
Established cardiovascular safety pathway — the SURPASS-CVOT outcomes trial has provided non-inferiority cardiovascular data in type 2 diabetes, and the GLP-1/GIP class has accumulated substantial real-world experience.
Patients with established type 2 diabetes — both Mounjaro (T2D) and Zepbound (obesity) are FDA-approved with extensive trial support across the SURPASS and SURMOUNT programs.
Maximum mean weight-loss magnitude in reported Phase 3 data — TRIUMPH-1 topline numbers from May 21 2026 include 28.3% mean weight loss at 12 mg over 80 weeks and 30.3% at 104 weeks in the BMI ≥35 subgroup, the largest effect size reported for any obesity pharmacotherapy. Patients enrolled in qualifying clinical trials may be the only path to legal access until FDA approval.
Cases where dual-agonist therapy has plateaued — the additional glucagon receptor agonism may produce additive weight-loss benefit, though this hypothesis has not been tested in head-to-head trials.
When tolerability has been the limiting factor at high incretin doses — the TRIUMPH-1 4 mg arm produced approximately 19% mean weight loss (vs 28.3% at 12 mg), suggesting a usable lower-dose tier that may carry a more favorable GI tolerability profile, pending full data at ADA 2026.